Download PDF
Appl Clin Inform 2020; 11(02): 366-373
DOI: 10.1055/s-0040-1710392
Invited Editorial
Georg Thieme Verlag KG Stuttgart · New York

From Commercialization to Accountability: Responsible Health Data Collection, Use, and Disclosure for the 21st Century

Deven McGraw
1   Ciitizen Corp., Palo Alto, California, United States
,
Carolyn Petersen
2   Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, United States
› Author Affiliations Funding None.
Further Information

Publication History

27 March 2020

06 April 2020

Publication Date:
20 May 2020 (online)

Also available at
   Permissions and Reprints

Introduction

Proposed initiatives in the U.S. that require sharing of clinical health information and facilitate easier access to that information through open, standard digital interfaces raise risks that sensitive information may be shared more broadly outside of legal protections for health data and may be more readily commercialized, in addition to existing commercialization of health data by health care institutions allowed by federal privacy laws. Is commercialization truly health data's “boogeyman” or is the problem the sharing of health data without sufficient protections against harm or inappropriate use? Can privacy risks be mitigated while still enabling value to be gleaned through more widespread sharing of health information? In this editorial, we argue that the focus should not be on whether the entity is or is not currently covered by federal health privacy laws, or whether the data are or are not “commercialized.” Instead, U.S. policies and practices should encourage (or outright require) (1) responsible use of data to improve health and health care, (2) greater transparency to and participation by patients and consumers, and (3) controls to minimize harm to individuals and populations.

Authors' Contributions

D.M. and C.P. wrote the first draft and revised the manuscript.


Protection of Human and Animal Subjects

This work involved no humans or animals, and so was not subject to institutional review board oversight.